Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBLN
Previous Symbol
CUSIPN/A
Phone760-795-6558
Debt
Debt-to-Equity Ratio0.47
Current Ratio4.85
Quick Ratio4.58
Price-To-Earnings
Trailing P/E Ratio-0.84
Forward P/E Ratio-0.91
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.91 million
Price / Sales4.12
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.54 per share
Price / Book1.14
Profitability
EPS (Most Recent Fiscal Year)($2.08)
Net Income$-34,760,000.00
Net Margins-178.84%
Return on Equity-80.38%
Return on Assets-47.23%
Miscellaneous
Employees113
Outstanding Shares23,280,000
Market Cap$40.04 million
OptionableOptionable
Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions
What is Obalon Therapeutics' stock symbol?
Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."
How were Obalon Therapeutics' earnings last quarter?
Obalon Therapeutics Inc (NASDAQ:OBLN) posted its quarterly earnings data on Friday, November, 2nd. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.11. The firm had revenue of $2.99 million for the quarter, compared to analysts' expectations of $2.45 million. Obalon Therapeutics had a negative return on equity of 80.38% and a negative net margin of 178.84%. View Obalon Therapeutics' Earnings History.
When is Obalon Therapeutics' next earnings date?
What price target have analysts set for OBLN?
5 equities research analysts have issued twelve-month price targets for Obalon Therapeutics' shares. Their forecasts range from $2.50 to $10.00. On average, they expect Obalon Therapeutics' share price to reach $5.10 in the next year. This suggests a possible upside of 191.1% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.
What is the consensus analysts' recommendation for Obalon Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obalon Therapeutics.
What are Wall Street analysts saying about Obalon Therapeutics stock?
Here are some recent quotes from research analysts about Obalon Therapeutics stock:
- 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (11/14/2018)
- 2. Northland Securities analysts commented, "We are tweaking our PT to $2.50, but maintain our Neutral stance." (9/12/2018)
- 3. BTIG Research analysts commented, "2Q18 results came in light. Though reordering trends were strong in the quarter (+220% sequentially), new accounts sold came in below our expectations. As the company remains in the early innings of its commercial ramp, it appears this quarter that there continues to be refinement of the sales pitch and go-to-market strategy. Going forward, much of the sales focus will be on more productive accounts with OBLN establishing new clinical programs to assist with imaging acquisition – the biggest barrier to initial uptake. We trim our FY18 revenue estimates once again as we think it will take more time for some of these initiatives to bear fruit. In thinking about shares, we think the upcoming investor call (perhaps early September) to more explicitly discuss the marketing strategy and/or PMA approval of the Navigator system in 1H19 may lift sentiment." (8/5/2018)
Has Obalon Therapeutics been receiving favorable news coverage?
News headlines about OBLN stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Obalon Therapeutics earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
Who are some of Obalon Therapeutics' key competitors?
Some companies that are related to Obalon Therapeutics include RenovaCare (RCAR), Alphatec (ATEC), RA Medical Systems (RMED), Sensus Healthcare (SRTS), Apollo Endosurgery (APEN), Arch Therapeutics (ARTH), STRATA Skin Sciences (SSKN), iCAD (ICAD), Endologix (ELGX), Invo Bioscience (IVOB), Pro-Dex (PDEX), Repro-Med Systems (REPR), CAS Medical Systems (CASM), Motus GI (MOTS) and SANUWAVE Health (SNWV).
Who are Obalon Therapeutics' key executives?
Obalon Therapeutics' management team includes the folowing people:
- Mr. Andrew P. Rasdal, CEO & Director (Age 60)
- Dr. Kelly Huang, Pres & COO (Age 49)
- Mr. Mark C. Brister, Chief Technology Officer (Age 56)
- Mr. William John Plovanic CFA, CFO & Sec. (Age 49)
- Mr. Todd Michael Wood, VP of Global Sales
When did Obalon Therapeutics IPO?
(OBLN) raised $75 million in an initial public offering (IPO) on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.
Who are Obalon Therapeutics' major shareholders?
Obalon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Interwest Venture Management Co. (15.26%), Vanguard Group Inc (1.91%), Hoylecohen LLC (0.49%), Renaissance Technologies LLC (0.35%) and Granite Investment Partners LLC (0.33%). Company insiders that own Obalon Therapeutics stock include Kim P Kamdar, Neil Drake, Parters Vii L P Domain and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.
Which institutional investors are buying Obalon Therapeutics stock?
OBLN stock was bought by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., Hoylecohen LLC, Granite Investment Partners LLC, Renaissance Technologies LLC and Vanguard Group Inc. Company insiders that have bought Obalon Therapeutics stock in the last two years include Kim P Kamdar, Neil Drake, Parters Vii L P Domain and William J Plovanic. View Insider Buying and Selling for Obalon Therapeutics.
How do I buy shares of Obalon Therapeutics?
Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Obalon Therapeutics' stock price today?
One share of OBLN stock can currently be purchased for approximately $1.7518.
How big of a company is Obalon Therapeutics?
Obalon Therapeutics has a market capitalization of $40.04 million and generates $9.91 million in revenue each year. The company earns $-34,760,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Obalon Therapeutics employs 113 workers across the globe.
What is Obalon Therapeutics' official website?
How can I contact Obalon Therapeutics?
Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 760-795-6558 or via email at [email protected]
MarketBeat Community Rating for Obalon Therapeutics (NASDAQ OBLN)
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
